Clinical trials: Remission of Ulcerative Colitis
Ulcerative Colitis
Berberine Chloride in Preventing Colorectal Cancer in Patients With Ulcerative Colitis in Remission
This randomized, pilot phase I trial studies the side effects of berberine chloride in treating patients with ulcerative colitis and who are in remission (a decrease in or disappearance of signs and symptoms of cancer) to reduce…
- Trial name
- NCT02365480
- Testing
- Berberine Chloride, Laboratory Biomarker Analysis
- Where
- 2 sites in United States, China
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Ulcerative Colitis in Remission
Evaluation of ProLife 10 FORTE on Gut Microbiota Composition in UC Patients
This clinical trial aims to learn if the probiotic Prolife 10 Forte could improve the Gut Microbiota composition of Ulcerative colitis patients during the remission phase.
- Trial name
- ProZ-UC (NCT06642883)
- Testing
- Prolife
- Where
- Italy
- Volunteers
- 70 people
- Sponsor
- University of Padova
Ulcerative Colitis
Study of Freeze-dried Black Raspberry in Maintenance of Ulcerative Colitis
This research study is about adding Black Raspberry powder to the treatment regimen of patients with ulcerative colitis who are currently in remission and doing well.
- Trial name
- BRB (NCT02267694)
- Testing
- Freeze-dried black raspberry powder
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- UConn Health
Ulcerative Colitis (UC)
Comparative Outcomes of Ulcerative Colitis Patients With Mayo Endoscopic Score 1 and Histologic Activity Versus Mayo Endoscopic Score 2
This retrospective study examines patients with ulcerative colitis who initiated advanced therapy for their disease. In clinical practice, patients with only mild inflammation on endoscopy (Mayo Endoscopic Subscore 1, or MES1)…
- Trial name
- NCT07188727
- Where
- Italy
- Volunteers
- 159 people
- Sponsor
- IRCCS San Raffaele
Ulcerative Colitis
PRObiotic VSL#3® for Maintenance of Clinical and Endoscopic REMission in Ulcerative Colitis
Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) characterized by chronic inflammation limited to colonic mucosa. Its pathogenesis is not still clear, even if a multifactorial aetiology has been advocated.
- Trial name
- PROREM UC (NCT03415711)
- Testing
- VSL#3®, Mesalamine
- Where
- Italy
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- VSL Pharmaceuticals
Ulcerative Colitis (UC)
STOP-UC: De-escalation of Therapy in Patients With Ulcerative Colitis With Histological Remission
The goal of this study is to better understand treatment strategies for people with ulcerative colitis (UC). Researchers will compare patients with UC in histologic remission (no evidence of inflammation or active disease on…
- Trial name
- NCT06693310
- Testing
- de-escalation or discontinuation of therapy, continuation of current therapy
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- University of Chicago
Ulcerative Colitis
Asacol Dosing Study for Active Ulcerative Colitis
We, the investigators at University of Washington, plan on evaluating the effect of open label Asacol at a dose of 4.8 grams/day divided BID (twice per day) or TID (three times per day) on its ability to induce remission in…
- Trial name
- NCT00194818
- Testing
- Asacol (mesalamine)
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Washington
Colitis, Ulcerative
Two Therapeutic Strategies for the Maintenance of Remission in Patients With Ulcerative Colitis
Ulcerative colitis patients treated with Infliximab (IFX) in deep remission after at least 12 months of treatment will be randomized to continue IFX or to stop IFX and start Azathioprine (AZA).
- Trial name
- SCILLA (NCT03151525)
- Testing
- Azathioprine, Infliximab
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Istituto Clinico Humanitas
Ulcerative Colitis in Remission
Impact of Bread Diet on Intestinal Dysbiosis and Irritable Bowel Syndrome Symptoms in Quiescent Ulcerative Colitis
The present study aimed to compare the in vivo prebiotic properties of bread produced by traditional breadmaking techniques with that made using a modern breadmaking method on Irritable Bowel Syndrome-like symptoms in patients…
- Trial name
- NCT05656391
- Testing
- Treatment vs control bread
- Where
- Spain
- Volunteers
- 31 people
- Sponsor
- Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta
Ulcerative Colitis
Mesalamine Pellet Formulation to Maintain Remission of Mild to Moderate Ulcerative Colitis
The purpose of this study is to compare the maintenance of mild to moderate ulcerative colitis remission with six months of treatment with 1.5 grams of mesalamine pellets each day versus placebo.
- Trial name
- NCT00744016
- Testing
- Granulated mesalamine
- Where
- United States
- Volunteers
- 305 people
- Sponsor
- Bausch Health Americas, Inc.
Ulcerative Colitis
A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
The main aim of this study is to learn about the effect of treatment with vedolizumab IV (vedolizumab) together with tofacitinib in adults with moderate and severe ulcerative colitis (UC).
- Trial name
- NCT06095128
- Testing
- Vedolizumab, Tofacitinib
- Where
- 45 sites in United States, Canada
- Volunteers
- 60 people
- Sponsor
- Takeda
Ulcerative Colitis
The Colitis Once Daily Asacol Study
The purpose of this study is to compare the safety and effectiveness of dosing mesalazine 800 mg tablets (Asacol®) at 2.4 g once daily versus divided doses three times daily in the maintenance of remission of ulcerative colitis.
- Trial name
- CODA (NCT00708656)
- Testing
- mesalazine (Asacol®)
- Where
- 45 sites in United Kingdom
- Volunteers
- 213 people
- Sponsor
- Cardiff and Vale University Health Board
Ulcerative Colitis
Efficacy, Safety and Tolerability of PF-06687234 as Add-on Therapy to Infliximab in Active UC Subjects Not in Remission.
The purpose of this study is to determine if PF-06687234 is effective and safe as add-on therapy to infliximab in subjects with active ulcerative colitis who are not in remission.
- Trial name
- NCT03269695
- Testing
- PF-06687234
- Where
- 34 sites in United States, Australia and 8 more
- Volunteers
- 20 people
- Sponsor
- Pfizer
Ulcerative Colitis
Evaluation of Histologic and Endoscopic Remission Induced by Infliximab in Moderate to Severe Ulcerative Colitis
The aim of this study is to assess the relationship between microscopic Geboes index of inflammation and clinical course of ulcerative colitis in patients treated with infliximab.
- Trial name
- HERICA (NCT01408810)
- Testing
- Infliximab
- Where
- Portugal
- Volunteers
- 21 people
- Sponsor
- Grupo de Estudo da Doença Inflamatória Intestinal
Inflammatory Bowel Disease, Ulcerative Colitis Type, Functional Disorder of Gastrointestinal Tract
Evaluation of the Effects of Colipral on Microbiota Gut Composition in Patients Presenting With Ulcerative Colitis During Remission Phase and Functional Disorders
The study is a double-blind, placebo-controlled, crossover, randomised trial, in which enrolled subjects will be included for 18 months.
- Trial name
- COLIPRAL (NCT07751081)
- Testing
- Food Supplement Colipral in film-coated tablets containing Escherichia coli 5C LMG S-33222
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- University of Padova
Ulcerative Colitis
A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors
This Phase III, double-blind, placebo and active-comparator controlled, multicenter study will investigate the efficacy and safety of etrolizumab in induction of remission in participants with moderately to severely active…
- Trial name
- HIBISCUS I (NCT02163759)
- Testing
- Adalimumab, Etrolizumab
- Where
- 88 sites in United States, Argentina and 12 more
- Volunteers
- 358 people
- Sponsor
- Hoffmann-La Roche
Ulcerative Colitis
Mesalamine 4 g Sachet for the Induction of Remission in Active, Mild to Moderate Ulcerative Colitis (UC)
The purpose of this trial is to investigate the efficacy of mesalamine for the induction of clinical and endoscopic remission in subjects with active, mild to moderate UC.
- Trial name
- NCT02522767
- Testing
- Mesalamine
- Where
- 93 sites in United States, Bulgaria and 9 more
- Volunteers
- 228 people
- Sponsor
- Ferring Pharmaceuticals